Research
Hormonal
The application of injectable agents is hindered by adverse effects, high costs, and accessibility issues.
Practitioners should consider these barriers when recommending injectable therapies for obesity.
StrongSupportsmedium confidence
Despite the therapeutic promise of injectable agents, their widespread application is hindered by adverse effects, high costs, and accessibility issues.
Why this rating
The claim is based on a review of the challenges associated with injectable agents.
Source
Injectables Pharmacotherapies for Obesity: Mechanisms, Efficacy, and Aesthetic Implications
Juan Marques Gomes et al. · Obesities · 2025
DOI 10.3390/obesities5020022
reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →